Literature DB >> 25450300

Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.

Kathleen E O'Neill1, Suneeta Senapati2, Anuja Dokras1.   

Abstract

OBJECTIVE: To compare endocrine profiles and IVF outcomes after using GnRH agonists (GnRHa) to trigger final oocyte maturation in women with polycystic ovary syndrome (PCOS) with other hyper-responders.
DESIGN: Retrospective cohort study.
SETTING: Academic center. PATIENT(S): Forty women with PCOS and 74 hyper-responders without PCOS. INTERVENTION(S): GnRHa trigger. MAIN OUTCOME MEASURE(S): Number of oocytes. RESULT(S): Serum E2, LH, and P levels on the day of GnRHa trigger and the day after trigger did not differ significantly between groups. There were no significant differences in total number of oocytes or percent mature oocytes obtained between groups after controlling for age, antral follicle count, and total days of stimulation. The overall rate of no retrieval of oocytes after trigger was low (2.6%). Fertilization, implantation, clinical pregnancy, and live-birth rates were similar in the two groups. No patients developed ovarian hyperstimulation syndrome (OHSS). CONCLUSION(S): The similar post-GnRHa trigger hormone profiles and mature oocyte yield support the routine use of GnRHa trigger to prevent OHSS in women with PCOS.
Copyright © 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GnRHa trigger; IVF outcomes; OHSS; PCOS

Mesh:

Substances:

Year:  2014        PMID: 25450300      PMCID: PMC4866644          DOI: 10.1016/j.fertnstert.2014.09.042

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  51 in total

1.  Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.

Authors:  B C Fauser; D de Jong; F Olivennes; H Wramsby; C Tay; J Itskovitz-Eldor; H G van Hooren
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 2.  Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles.

Authors:  C Yding Andersen
Journal:  Reprod Biomed Online       Date:  2002 Nov-Dec       Impact factor: 3.828

Review 3.  Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.

Authors:  Shahar Kol
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

4.  FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatory follicles.

Authors:  J J Eppig
Journal:  Nature       Date:  1979-10-11       Impact factor: 49.962

5.  'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome.

Authors:  P E Egbase; M Al-Sharhan; J G Grudzinskas
Journal:  Hum Reprod       Date:  2002-05       Impact factor: 6.918

6.  Role of carbohydrate of human chorionic gonadotropin in the mechanism of hormone action.

Authors:  W R Moyle; O P Bahl; L März
Journal:  J Biol Chem       Date:  1975-12-10       Impact factor: 5.157

7.  Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin.

Authors:  Ori Nevo; Talia Eldar-Geva; Shahar Kol; Joseph Itskovitz-Eldor
Journal:  Fertil Steril       Date:  2003-05       Impact factor: 7.329

8.  Hormonal dynamics at midcycle: a reevaluation.

Authors:  J D Hoff; M E Quigley; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

9.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

10.  Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs.

Authors:  Haiyan Lin; Yu Li; Lin Li; Wenjun Wang; Dongzi Yang; Qingxue Zhang
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more
  7 in total

1.  Age-Related Normogram for Ovarian Antral Follicle Count in Women with Polycystic Ovary Syndrome and Comparison with Age Matched Controls Using Magnetic Resonance Imaging.

Authors:  Senthil Kumar Aiyappan; Bulabai Karpagam; V Vadanika; Prem Kumar Chidambaram; S Vinayagam; K C Saravanan
Journal:  J Clin Diagn Res       Date:  2016-01-01

Review 2.  Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Authors:  Hadas Ganer Herman; Eran Horowitz; Yossi Mizrachi; Jacob Farhi; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2022-03-19       Impact factor: 3.412

Review 3.  Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic.

Authors:  Manish Banker; Juan A Garcia-Velasco
Journal:  J Hum Reprod Sci       Date:  2015 Jan-Mar

4.  Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization Cycles Provides a Better Cycle Outcome - A proof-of-concept Study.

Authors:  Krishna Deepika; Pookilath Baiju; Praneesh Gautham; Rathore Suvarna; Vohra Arveen; Rao Kamini
Journal:  J Hum Reprod Sci       Date:  2017 Oct-Dec

5.  Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome.

Authors:  Selçuk Selçuk; Enis Özkaya; Ahmet Eser; Melda Kuyucu; Hüseyin Tayfun Kutlu; Belgin Devranoğlu; Kenan Sofuoğlu; Vedat Erkan Dayıcıoğlu
Journal:  Turk J Obstet Gynecol       Date:  2016-03-10

6.  Does the repeat dose of gonadotropin-releasing hormone agonist trigger in polycystic ovarian syndrome improve in vitro fertilization cycles outcome? A clinical trial study.

Authors:  Abbas Aflatoonian; Fatemeh Haghighi; Masrooreh Hoseini; Saeid Haghdani
Journal:  Int J Reprod Biomed       Date:  2020-07-22

7.  The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.

Authors:  Xiuxian Zhu; Hongjuan Ye; Yonglun Fu
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.